NOVN(Delisted)
NVN Liquidation·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NOVN
Nvn Liquidation, Inc.
A medical dermatology company primarily focused on innovative therapeutic products for skin diseases
P.O. Box 64, Pittsboro, North Carolina 27312
--
NVN Liquidation, Inc., was incorporated under the laws of the State of Delaware in January 2006. The Company is a late-stage pharmaceutical company dedicated to redefining the standard of skin care through the development and commercialization of innovative therapies utilizing the Nitrogen Oxide Technology Platform. Two key components of the company's nitric oxide technology platform are the company's proprietary Nitricil technology. The company is rapidly advancing five dermatological treatment programs with significant market demand. The company's lead product is SB204, an elegant cosmetic topical gel for the treatment of acne, the most common skin disease in the United States, for a variety of skins.
Company Financials
EPS
NOVN has released its 2023 Q1 earnings. EPS was reported at -0.54, versus the expected -0.32, missing expectations. The chart below visualizes how NOVN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NOVN has released its 2023 Q1 earnings report, with revenue of 3.17M, reflecting a YoY change of 64.21%, and net profit of -14.12M, showing a YoY change of -5.52%. The Sankey diagram below clearly presents NOVN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
